公开(公告)号：EP3936526A1

公开(公告)日：2022-01-12

申请号：EP20766028.3

申请日：2020-03-05

申请人： Jiangsu Hengrui Medicine Co., Ltd. ,  Shanghai Hengrui Pharmaceutical Co., Ltd.

发明人： GU, Xiaoling ,  YE, Xin ,  HU, Bing ,  GE, Hu ,  TAO, Weikang

IPC分类号： C07K19/00 ,  C12N15/62 ,  A61K39/395 ,  A61P35/00

摘要： Provided are a bifunctional fusion protein and pharmaceutical use thereof. Specifically, provided are a bifunctional fusion protein comprising an SIRPγ peptide variant and an anti-human PD-L1 antibody, an SIRPγ peptide variant, and pharmaceutical use thereof. The bifunctional fusion protein can specifically bind PD-L1 and CD47 to block the binding of PD-L1 or CD47 to a receptor or ligand thereof. In addition, also provided are preparation and application of the bifunctional fusion protein, and treatment of cancers and immune-related diseases.